Data were available for 70 patients

Data were available for 70 patients: median age 71.9 years (IQR 62.7–79.0), weight 80 kg (IQR 71–95), CHA2DS2-VASc score 3 (IQR 2–4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16/70) had discontinued treatment with dabigatran; four due to predominantly gastrointestinal side effects, three due to bleeding (one severe), one as a result of adverse media coverage with the remainder comprising planned treatment
discontinuation and undetermined. In total, 29% reported bleeding events, predominantly minor bleeding and bruising. There were no cerebrovascular events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses. Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran.

ผลลัพธ์ (อังกฤษ) 2:

Data were available for 70 patients: median age 71.9 years (IQR 62.7-79.0), weight 80 kg (IQR 71-95), CHA2DS2-VASc score 3 (IQR 2-4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16/70) had discontinued treatment with dabigatran; Due to predominantly gastrointestinal effects Side Four, Three Due to bleeding (one severe), one as a Result of adverse Media coverage with the remainder comprising planned Treatment
Discontinuation and undetermined. In total, 29% reported bleeding events, predominantly minor bleeding and bruising. There were no cerebrovascular events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses. Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran.

ผลลัพธ์ (อังกฤษ) 3:

Data were available for 70 patients: median age 71.9 years (IQR 62.7 - 79.0), weight 80 kg (IQR 71 - 95), CHA2DS2-VASc score 3 (IQR. 2 - 4). Seventy-one percent of patients reported adverse events although the majority were minor. Twenty-four percent (16 / 70). Had discontinued treatment with dabigatran; four due to predominantly gastrointestinal side effects, three due to bleeding EOS (one severe) theOne as a result of adverse media coverage with the remainder comprising planned treatment
discontinuation and, undetermined. In total 29% reported, bleeding events predominantly minor, bleeding and bruising. There were no cerebrovascular, events. Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses.Seventy-seven percent reported treatment satisfaction and 79% of those previously treated with warfarin preferred dabigatran.
.